| Full text | |
| Author(s): Show less - |
Almeida-Afonso, Rosa
[1, 2]
;
Finamor, Danilo
[2]
;
Fonseca, Luiz Augusto M.
[1]
;
Rocha Veiga, Ana P.
[1]
;
Monteiro, Mariana A.
[1]
;
Magri, Marcello
[1]
;
Duarte, Alberto J. S.
[1]
;
Casseb, Jorge
[1]
;
Clinicas, Hosp
;
Dermatol, Serv
;
LIM56, Fac Med
;
Paulo, Inst Med Tropical Sao
;
Paulo, Univ Sao
Total Authors: 13
|
| Affiliation: | [1] Univ Sao Paulo, Hosp Clin, Dept Dermatol, Fac Med, Sao Paulo, SP - Brazil
[2] Ctr Referencia IST AIDS, Sao Paulo, SP - Brazil
Total Affiliations: 2
|
| Document type: | Journal article |
| Source: | Brazilian Journal of Infectious Diseases; v. 25, n. 3 MAY-JUN 2021. |
| Web of Science Citations: | 0 |
| Abstract | |
ABSTRACT Hypovitaminosis D is now considered a pandemic, especially among more vulnerable populations and in HIV-infected subjects, with 80% presenting levels below 30 ng/mL. As there is no consensus on the more adequate dosage needed to correct such deficiency, the objective of this study was to evaluate 25 (OH) vitamin D supplementation in HIV-1 patients deficient of vitamin D. A total of 73 HIV-1-infected patients were included, drawn from a cohort of 435 patients; 37 patients were randomized to the active group, supplemented once a week with 50,000 UI vitamin D by mouth (group 1) and 36 to the placebo group (group 2). The study period ranged from June 2016 to September 2017. Variables involved in vitamin D metabolism and risk factors associated with hypovitaminosis were evaluated. The mean age was 45 years and 31.5 % were women. Vitamin D supplementation was effective in normalizing serum levels after six months in group 1 (mean 35 ng/mL compared to 21 ng/mL for the placebo group; p= 0.04). No patient reached blood levels considered toxic (>100 UI). Efavirenz use can negatively influence vitamin D levels and supplementation is necessary as a likely adjunct to improving CD4+ T cells, resulting in greater effectiveness of the treatment. A weekly oral dose of 50,000 IU of vitamin D was sufficient to normalize the vitamin deficiency, safely and with good adherence among persons living with HIV/AIDS in Brazil. (AU) | |
| FAPESP's process: | 18/07239-2 - Incidence, risk factors, and pathogenic mechanism of neurocognitive disorders (HAND) among HIV-1-infected subjects |
| Grantee: | Jorge Simao do Rosario Casseb |
| Support Opportunities: | Research Projects - Thematic Grants |